A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications
work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment
for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both
heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by
the formation of a blood clot in an artery that partially or totally blocks the blood supply
to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine
which drug, when either is used in conjunction with aspirin, is better at reducing deaths
from vascular causes, future heart attacks and/or strokes in patients with ACS.